Skip to main content

Market Overview

Moderna Plans COVID-19 Booster Shots: What You Need To Know

Moderna Plans COVID-19 Booster Shots: What You Need To Know

Moderna Inc. (NASDAQ: MRNA) is planning to test the efficacy of COVID-19 vaccine booster shots a year after initial doses of the vaccine have been administered to an individual, CNBC reported Thursday.

What Happened: The biotech company expects to begin the booster study in adult participants in July, its CEO Stéphane Bancel disclosed in a corporate presentation at the 39th Annual J.P. Morgan Healthcare Conference on Monday.

Moderna Chief Medical Officer Tal Zaks said at the conference the company expects the immunity generated from the vaccine to last at least a year, CNBC reported. Zaks added that Moderna would make a “data-based recommendation” on the degree to which booster shots might be needed.

The first participants in the Moderna COVID-19 vaccine trial received their shots in March, CNBC noted. Those who received less than the 100 micrograms dose authorized ultimately by the Food and Drug Administration will receive their booster trial shot earlier than a year, while those who received shots of 100 micrograms or more will be administered the booster dose at the one year mark.

See Also: FDA Warns Against Tinkering With Pfizer, Moderna Vaccine Regimens After White House Advisor's Comments

Why It Matters: Moderna COVID-19 vaccine received the FDA emergency use authorization in December and is the only such authorized vaccine currently besides Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX)’s candidate.

Medical experts have been looking into how long the neutralizing antibodies generated by COVID-19 vaccines would last. 

Preliminary analysis in a  relatively small study by the New England Journal of Medicine suggested that — for some in the older population — the immunization could last less than a year, as reported by Forbes.

Bancel earlier this month said Moderna's COVID-19 vaccine could provide protection for a couple of years but added more data was needed to make a definite statement, as reported by Reuters.

Price Action: Moderna shares closed 4.5% higher at $129.72 on Thursday. The shares added another 0.6% in the after-hours session.

See Also: Moderna Teams Up With Uber On COVID-19 Vaccination: What You Need To Know


Related Articles (MRNA)

View Comments and Join the Discussion!

Posted-In: Covid-19 VaccinesBiotech News Media General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at